Acrivon Therapeutics annual capital expenditures (capex)
2021
2022
2023
2024
2025
Acrivon Therapeutics Capital Expenditures (CapEx) Growth & History (ACRV)
Acrivon Therapeutics's capital expenditures (capex) was $1.7M for fiscal 2025.
View full Acrivon Therapeutics company overviewAcrivon Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.7M | −$1.1M | −39.70% |
| 2024 | 2024-12-31 | $2.8M | $1.5M | +114.91% |
| 2023 | 2023-12-31 | $1.3M | −$878,000 | −40.54% |
| 2022 | 2022-12-31 | $2.2M | $1.9M | +810.08% |
| 2021 | 2021-12-31 | $238,000 | — | — |
Acrivon Therapeutics quarterly capital expenditures (capex)
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $87,000 | −$406,000 | −82.35% |
| Q1 2026 | 2026-03-31 | $14,000 | −$44,000 | −75.86% |
| Q4 2025 | 2025-12-31 | $219,000 | −$608,000 | −73.52% |
| Q3 2025 | 2025-09-30 | $899,000 | −$90,000 | −9.10% |
| Q2 2025 | 2025-06-30 | $493,000 | $356,000 | +259.85% |
| Q1 2025 | 2025-03-31 | $58,000 | −$757,000 | −92.88% |
| Q4 2024 | 2024-12-31 | $827,000 | −$324,000 | −28.15% |
| Q3 2024 | 2024-09-30 | $989,000 | $989,000 | — |
| Q2 2024 | 2024-06-30 | $137,000 | $25,000 | +22.32% |
| Q1 2024 | 2024-03-31 | $815,000 | $790,000 | +3160.00% |
| Q4 2023 | 2023-12-31 | $1.2M | $900,000 | +358.57% |
| Q3 2023 | 2023-09-30 | $0 | −$426,000 | — |
| Q2 2023 | 2023-06-30 | $112,000 | −$962,000 | −89.57% |
| Q1 2023 | 2023-03-31 | $25,000 | −$390,000 | −93.98% |
| Q4 2022 | 2022-12-31 | $251,000 | — | — |
| Q3 2022 | 2022-09-30 | $426,000 | — | — |
| Q2 2022 | 2022-06-30 | $1.1M | — | — |
| Q1 2022 | 2022-03-31 | $415,000 | — | — |
Acrivon Therapeutics capital expenditures (capex) trends
Between the periods ended 2021-12-31 and 2025-12-31, Acrivon Therapeutics's capital expenditures (capex) increased from $238,000 to $1.7M, a change of $1.4M. The latest reported quarter, Q2 2026, shows $87,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acrivon Therapeutics source filings ↗